Provided by Tiger Trade Technology Pte. Ltd.

Protagenic Therapeutics Inc

0.4000
-0.0027-0.67%
Volume:17.76K
Turnover:6.85K
Market Cap:773.95K
PE:-0.08
High:0.4100
Open:0.4028
Low:0.3726
Close:0.4027
52wk High:14.28
52wk Low:0.2601
Shares:1.93M
Float Shares:1.91M
Volume Ratio:1.28
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3030
EPS(LYR):-15.7868
ROE:-512.79%
ROA:-189.60%
PB:-8.76
PE(LYR):-0.03

Loading ...

Protagenic Therapeutics Faces Nasdaq Delisting Over Listing Rule Violations

Reuters
·
Jan 05

Protagenic Therapeutics Reports Positive Phase 1 Results for PT00114 in Stress-Related Psychiatric Disorders

Reuters
·
Dec 09, 2025

Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Dec 06, 2025

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires Live
·
Nov 28, 2025

Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues

MT Newswires Live
·
Nov 28, 2025

Protagenic Therapeutics Delays Quarterly Financial Report

Reuters
·
Nov 27, 2025

Protagenic Therapeutics Delays Quarterly Report Filing

Reuters
·
Nov 15, 2025

Protagenic Therapeutics Completes Dosing in Phase 1 Study of Lead Compound PT00114

Reuters
·
Nov 13, 2025

Jennifer Chao Resigns from Protagenic Therapeutics Board

Reuters
·
Nov 06, 2025

Protagenic Therapeutics Inc: Files Complaint to Rescind Share Exchange Agreement by Which Co Acquired Phytanix Bio - SEC Filing

THOMSON REUTERS
·
Nov 01, 2025

Protagenic Therapeutics: May Offer and Sell Shares of Common Stock of up to $1.75 Mln - SEC Filing

THOMSON REUTERS
·
Oct 25, 2025

Protagenic Therapeutics Files Initial Beneficial Ownership Statement; Ex-CEO and Director Barrett Evans Named as 10% Owner

Reuters
·
Oct 25, 2025

Top Midday Gainers

MT Newswires Live
·
Aug 22, 2025

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026

Reuters
·
Aug 21, 2025

Protagenic Therapeutics Inc. Delays Q2 Financial Report Due to Transition to Virtual Operating Model

Reuters
·
Aug 15, 2025

BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing

Reuters
·
Aug 14, 2025

Protagenic Therapeutics to Pause Trials, Remove CEO in Restructuring

Dow Jones
·
Aug 14, 2025

Protagenic Therapeutics Inc: Has Temporarily Suspended Expenditures Related to Preclinical Programs

THOMSON REUTERS
·
Aug 14, 2025

Protagenic Therapeutics : Terminated Employment of Barrett Evans as CEO and President and Colin Stott as Chief Operating Officer

THOMSON REUTERS
·
Aug 14, 2025

Protagenic Therapeutics:All Preclinical Programs Originated With Former Phytanix Bio (Phyx-001,Phyx-002,Phyx-003,Phyx-004, Phyx-005) Have Been Paused

THOMSON REUTERS
·
Aug 14, 2025